Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus. It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells."[1][2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | CD19 and Fc gamma receptor IIb |
| Clinical data | |
| Other names | AMG 729 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
References
edit- ^ Perugino, Cory A; Wallace, Zachary S; Zack, Debra J; Quinn, Shauna M; Poma, Allen; Fernandes, Ana D; Foster, Paul; DeMattos, Steve; Burington, Bart; Liu, Hang; Allard-Chamard, Hugues; Smith, Nathan; Kai, Xin; Xing, Kelly; Pillai, Shiv; Stone, John H (August 2023). "Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial". The Lancet Rheumatology. 5 (8): e442–e450. doi:10.1016/S2665-9913(23)00157-1. PMID 38251576. S2CID 260176880.
- ^ Merrill, Joan T.; Guthridge, Joel; Smith, Miles; June, Joshua; Koumpouras, Fotios; Machua, Wambui; Askanase, Anca; Khosroshahi, Arezou; Sheikh, Saira Z.; Rathi, Gaurav; Burington, Bart; Foster, Paul; Matijevic, Mark; Arora, Sujata; Wang, Xiaodong; Gao, Minggeng; Wax, Stephen; James, Judith A.; Zack, Debra J. (December 2023). "Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind , Randomized, Placebo-Controlled , Phase 2 Trial". Arthritis & Rheumatology. 75 (12): 2185–2194. doi:10.1002/art.42652. S2CID 265521796.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |